Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

NCT05918094 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05918094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Recruiting
Start date
April 30, 2023
Completion date
December 31, 2028
Enrollment
540 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer